Hematologic Oncology

Findings from a phase 1b trial showed that the addition of obinutuzumab to ibrutinib produced a complete response rate that compared favorably with what has historically been observed with ibrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia.

Camidanlumab tesirine induced an overall response rate of 70.1% in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma who previously received brentuximab vedotin and a PD-1 blockade with or without stem cell transplant.

Despite receiving similar treatment, Black patients between the ages of 18 and 29 years with acute myeloid leukemia were twice as likely to die within 5 years compared with Whites.

Judith Karp, MD; Azra Raza, MD; and Michelle M. Le Beau, PhD, share the challenges they chose to mold into career goals, including developing a new technology to study cell cytokinetics, identifying gene phenotypes, and recognizing that leukemia diseases stem from the same root issues in DNA.

Ehab Atallah, MD, explains how patient characteristics influence current treatment strategies in acute myeloid leukemia, how frontline pirtobrutinib may move toward use in chronic lymphocytic leukemia, and the growing evidence favoring CAR T-cell therapy as an effective treatment option in CLL.

Shared insight on standard-of-care prophylactic methods employed in the management of patients with graft versus host disease.

Expert panelists spearhead a discussion on the pathophysiology driving both acute and chronic graft versus host disease.

The CAR T-cell therapy anbalcabtagene autoleucel generated strong overall response rates in patients with relapsed/refractory large B-cell lymphoma.

Judith Karp, MD; Azra Raza, MD; and Michelle M. Le Beau, PhD, highlight the decades-long evolution of the leukemia field and express challenges such as defining the causes of leukemia and developing therapies to treat the disease and mitigate adverse effects like bone pain.

The addition of belantamab mafodotin-blmf to lenalidomide and dexamethasone generated responses with acceptable safety in patients with newly diagnosed multiple myeloma who were ineligible to undergo autologous stem cell transplant.

Dr. Pau Montesinos reviews the efficacy of ivosidenib and azacitidine in reducing transfusions and improving blood counts in patients with newly diagnosed acute myeloid leukemia.

Real-world evidence is finding an expanded role in oncology, prompting experts to rethink how data are gathered on the day-to-day usefulness of drugs for regulatory decisions.

Jennifer Atlas, MD, presents the case of a 66-year-old woman with locally advanced basal cell carcinoma not responding to frontline treatment.

Oncologists discuss the efficacy and safety of a tafasitamab plus lenalidomide for relapsed/refractory DLBCL and share personal experiences relevant to its use.

Expert perspectives on how to identify chronic or persistent disease in patients diagnosed with immune thrombocytopenia.

Caron Jacobson, MD, and Matthew Lunning, DO, FACP, assess the available treatment options for patients with R/R DLBCL.

A commentary on the significance of the patient’s age in treating and managing ITP.

The FDA has accepted a biologics license application and granted a priority review designation to mosunetuzumab, a potential first-in-class CD20 and CD3 T-cell engaging bispecific antibody, for the treatment of patients with relapsed/refractory follicular lymphoma following at least 2 prior systemic therapies.

Daniel Pollyea, MD, MS, reviews the ongoing SELECT-AML-1 trial and comments on novel therapies and biomarkers in patients with newly diagnosed unfit AML.

Stephen J. Schuster, MD, discusses the implications of the FDA approval of tisagenlecleucel on the treatment strategy for relapsed/refractory follicular lymphoma and the next steps for tisa-cel.

Bijal Shah, MD, MS, discusses the long-term data from the ZUMA-3 trial of brexucabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia and spotlighted additional areas ripe for further exploration.

The FDA has warned that treatment with duvelisib has shown a possible increased risk of death and serious adverse effects compared with ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

The FDA has granted an orphan drug designation to evorpacept, a next-generation CD47 blocker, for use as a potential therapeutic option for patients with acute myeloid leukemia.

Genmab A/S shared plans to submit a biologics license application to the FDA seeking the approval of subcutaneous epcoritamab for the treatment of patients with relapsed or refractory large B-cell lymphoma in the second half of 2022.

Ajai Chari, MD, discusses the evolving landscape and developing therapies within multiple myeloma.